Novo Nordisk currently trades with a PE to growth ratio of 2.29, based on Aug 14, 2026 data. Dividing the 11.46 PE ratio by the 5.0% earnings growth rate produces this figure. Relative to the 3.18 average from the past four quarters, the PEG ratio is down by 28%.
Historically, Novo Nordisk has a PEG ratio averaging 3.27 across the last ten years. At 2.29, today's PEG ratio sits 30% less than its historical average. The ten years high came in the Mar 2019 quarter at 16.69, reflecting peak valuation relative to growth. The bottom was reached in the Mar 2026 quarter at 0.52, suggesting attractive value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 8.25 | 14.03 | 1.7% |
| 2024 | 1.27 | 27.21 | 21.4% |
| 2023 | 0.72 | 37.4 | 52.3% |
| 2022 | 2.14 | 38.31 | 17.9% |
| 2021 | 2.28 | 35.54 | 15.6% |
| 2020 | 2.42 | 23.67 | 9.8% |
| 2019 | 9.46 | 23.65 | 2.5% |
| 2018 | 4.81 | 18.77 | 3.9% |
| 2017 | 8 | 21.61 | 2.7% |
| 2016 | 1.64 | 16.89 | 10.3% |
| 2015 | 0.74 | 26.76 | 36% |
| 2014 | 4.1 | 26.25 | 6.4% |
| 2013 | 1.04 | 21.03 | 20.2% |
| 2012 | 0.76 | 22.33 | 29.5% |
| 2011 | 0.94 | 20.42 | 21.8% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 2.39 | 11.97 | 5% |
| Mar 2026 | 0.52 | 8.73 | 16.8% |
| Dec 2025 | 8.25 | 14.03 | 1.7% |
| Sep 2025 | 1.54 | 15.12 | 9.8% |
| Jun 2025 | 0.73 | 17.58 | 24% |
| Mar 2025 | 1.15 | 20.35 | 17.7% |
| Dec 2024 | 1.27 | 27.21 | 21.4% |
| Sep 2024 | 1.42 | 37.99 | 26.7% |
| Jun 2024 | 1.42 | 49.33 | 34.8% |
| Mar 2024 | 0.94 | 44.43 | 47.4% |
| Dec 2023 | 0.72 | 37.4 | 52.3% |
| Sep 2023 | 0.87 | 38.23 | 43.9% |
| Jun 2023 | 1.08 | 37.1 | 34.5% |
| Mar 2023 | 1.57 | 40.11 | 25.5% |
| Dec 2022 | 2.14 | 38.31 | 17.9% |
When comparing to historical data, NVO's PEG ratio sits above the 3 and 5-year averages, but it is lower than the 10-year average.
With a PEG of 2.29, NVO stands higher than the Healthcare sector, the industry and its peers average. Looking at the Healthcare sector average of 0.62, Novo Nordisk's PEG is 269% higher.
Compared to its peers, NVO has a PEG ratio lower than stock REGN, while greater than LLY's and AZN's. At 2.29, Novo Nordisk's PEG ratio is higher than the peer group average of 0.57.
According to Aug 14, 2026 figures, NVO's PEG ratio stands at 2.29.
Historical data over a 3-year period puts NVO's average PEG ratio at 1.77.
Historical data over a 5-year period puts NVO's average PEG ratio at 1.85.
NVO's PEG ratio topped out at 16.69 during the Mar 2019 quarter - the highest in ten years.
Compared to the 10-year average, NVO's PEG ratio stands 30% lower.
The elevated PEG ratio of 2.29 indicates that NVO may be priced above its earnings growth potential.
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Aug 14, 2026, Novo Nordisk has a PE ratio of 11.46. Earnings grew at 5.0% over the TTM period ending Jun 2026. Applying the formula, this gives a PEG ratio of 2.29. PEG RATIO(2.29) = PE RATIO(11.46) / EPS GROWTH(5.0%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.